FDA Cites PReye, LLC in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug
TL;DR
At a glance: The FDA Center for Drug Evaluation and Research issued a warning letter to PReye, LLC (Owner: Dr. Melinda C. O'Rourke, Wheat Ridge, CO, FEI 3031057987) on August 18, 2026 (Reference 320-26-118) following an inspection March 17-19, 2026, citing significant CGMP violations for finished pharmaceuticals and identification of an unapproved new drug. Violations included: repackaging sterile drug products in an unclassified office space using a non-certified flow hood lacking HEPA filtration and inadequate aseptic processing controls; absence of a functional quality control unit with required procedures (complaint review, supplier qualification, release testing, batch tracking); and marketing "PReye Vitamin SEE" as an unapproved new drug via website essencelaser.com/vitaminsee/ reviewed in June 2026. The letter states the drug products are adulterated under 21 U.S.C. 351(a)(2)(B) and the unapproved drug violates 21 U.S.C. 331(d) and 355(a), warning that failure to address violations may result in seizure or injunction without further notice.
Argus analysis
# FDA Warning Letter Analysis: PReye, LLC
**Company and Violations**
PReye, LLC, a drug repackaging operation owned by Dr. Melinda C. O'Rourke in Wheat Ridge, Colorado, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on August 18, 2026. An FDA inspection conducted March 17–19, 2026, identified significant Current Good Manufacturing Practice (CGMP) violations in the manufacturing and handling of sterile pharmaceutical products. The company operated as a drug repacker for its co-located med spa, Essence Laser and Wellness. Additionally, FDA's June 2026 website review identified "PReye Vitamin SEE," an ophthalmic product, as an unapproved new drug marketed with disease-prevention claims.
**Regulatory Citations and Implications**
The violations cited under 21 CFR parts 210 and 211 addressed two primary deficiencies. First, aseptic processing operations occurred in an unclassified office space using a non-certified flow hood without HEPA filtration—violating 21 CFR 211.42(c)(10) and 211.63 requirements for adequate, controlled manufacturing environments. Second, the firm lacked a functional quality control unit, failing 21 CFR 211.22 obligations to establish procedures for batch testing, complaint handling, supplier qualification, and deviation management. The unapproved new drug violation under 21 U.S.C. 355(a) stems from marketing claims that the product treats or prevents eye disease (cataracts, macular degeneration) without FDA approval.
**Response and Industry Monitoring**
The company committed in its March 22, 2026 response to cease manufacturing and distribution of PReye Vitamin SEE for the U.S. market. The warning letter requires notification before resuming any drug manufacturing. Compliance officers in sterile pharmaceutical and ophthalmic sectors should monitor whether PReye engages a qualified CGMP consultant and whether the company attempts to resume operations. The letter's emphasis on container-closure integrity and microbiological contamination risk for ophthalmic products reflects FDA's heightened concern for sterile eye preparations.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER PReye, LLC MARCS-CMS 732141 — August 18, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE Reference #: 320-26-118 Product: Drugs Recipient: Recipient Name Dr. Melinda C. O’Rourke Recipient Title Owner PReye, LLC 4855 Ward Rd. Wheat Ridge , CO 80033 United States (b)(6) Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 18, 2026 WARNING LETTER Reference number: 320-26-118 To Dr. Melinda C. O’Rourke: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products and facilities. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice including, without limitation, seizure and injunction. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, PReye, LLC, FDA Establishment Identifier (FEI) 3031057987, at 4855 Ward Road, Wheat Ridge, from March 17 to 19, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). In addition, violations were identified and documented during the review of your website https://essencelaser.com/vitaminsee/ in June 2026. Based on our review, “PReye Vitamin SEE” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). We reviewed your March 22, 2026, response to our Form FDA 483 in detail. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. CGMP Violations 1. Your firm failed to perform operations within spec…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has PReye, LLC had FDA enforcement actions before?
- Yes. Argus HQ has recorded 2 total FDA actions tied to PReye, LLC: 1 warning letter, 1 recall, and 0 approval records.
- What FDA violations was PReye, LLC cited for?
- The FDA Warning Letter to PReye, LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to PReye, LLC?
- FDA issued the letter (MARCS-CMS 732141) on 2026-08-18 and posted it publicly on fda.gov on 2026-09-01.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites PReye, LLC in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-preye-llc-2026-08-18-cgmp
"FDA Cites PReye, LLC in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-preye-llc-2026-08-18-cgmp.
Argus HQ Research. "FDA Cites PReye, LLC in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-preye-llc-2026-08-18-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_preye_llc_2026_08_18_cgmp_2026,
title = {FDA Cites PReye, LLC in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-preye-llc-2026-08-18-cgmp},
note = {Accessed: September 2, 2026}
}